Monopar starts rolling NDA for Wilson disease drug ALXN1840, reports Q2 2026 results
The company said it began a rolling FDA submission for ALXN1840 in July, backed by Rare Pediatric Disease designation and new Phase 3 data, with cash of $134.3 million.
SEC filing